Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
NOVN | Switzerland | CHF | Delayed | |
NOVNEE | Switzerland | CHF | Delayed | |
NOVNz | BATS Europe | CHF | Delayed | |
NVSEF | OTC Markets | USD | Delayed | |
NVS | NYSE | USD | Real-time | |
0QLR | London | CHF | Real-time | |
NVSN | Mexico | MXN | Delayed | |
NVSy | TradeGate | EUR | Delayed | |
NVSm | Buenos Aires | ARS | Delayed | |
N1VS34 | B3 | BRL | Delayed |
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Name | Age | Since | Title |
---|---|---|---|
Joerg Reinhardt | 66 | 1999 | Independent Non-Executive Chairman |
Daniel L. Vasella | 69 | 1996 | Honorary Chairman |
Simon E. Moroney | 63 | 2020 | Independent Vice Chairman of the Board |
Ton Buechner | 57 | 2016 | Independent Non-Executive Director |
Elizabeth Doherty | 65 | 2016 | Independent Non-Executive Director |
Patrice Bula | 66 | 2019 | Lead Independent Director |
Nancy C. Andrews | 65 | 2015 | Independent Non-Executive Director |
Daniel Hochstrasser | - | 2022 | Independent Director |
François Adrianus van Houten | 63 | 2017 | Independent Non-Executive Director |
Charles L. Sawyers | 64 | 2013 | Independent Non-Executive Director |
William Thomas Winters | 62 | 2013 | Independent Non-Executive Director |
Bridgette P. Heller | 62 | 2020 | Independent Non-Executive Director |
John D. Young | 60 | 2023 | Non-Executive & Independent Director |
Sidonie Golombowski-Daffner | - | - | Chairperson & President of Advanced Accelerator Applications |
Ana María de Pro Gonzalo | 57 | 2022 | Non-Executive & Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review